JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform
September 29, 2016 6:53 AM EDT
SunTrust Robinson Humphrey downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Buy to Neutral with a price target of $15.00 (from $60.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $42.35 yesterday.
...
More
September 28, 2016 4:03 PM EDT
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the... More
September 28, 2016 4:00 PM EDT
Intra-Cellular Therapies (NASDAQ: ITCI) trading halted with news pending.
...
More
